Eslicarbazepine acetate was effective when used as an add-on treatment for patients with drug-resistant focal epilepsy, according to authors of a Cochrane review published in Cochrane Database Systematic Reviews.
While most patients with epilepsy have a good prognosis, up to 30% of patients with epileptic seizures have drug-resistant epilepsy, which can adversely impact their psychosocial, psychiatric, and medical status. Eslicarbazepine acetate, an antiepileptic drug that blocks voltage-gated sodium channels, has been suggested to reduce seizure frequency in these patients.
The objective of the current updated version of a Cochrane Review originally published in 2011 was to determine the efficacy and tolerability of eslicarbazepine acetate when used in combination with other medications for patients with drug-resistant focal epilepsy.